Results 101 to 110 of about 10,042 (139)
Some of the next articles are maybe not open access.
Hämostaseologie, 2012
SummaryThe antithrombotic therapy in patients with atherosclerotic vascular disease is subject of several new therapeutic approaches. Simultaneous treatment with aspirin and a thienopyridin (clopidogrel) represents the standard of care for patients with acute coronary syndrome and following coronary stenting recommended by many guidelines. Without true
Antonio, Tello-Montoliu +2 more
+10 more sources
SummaryThe antithrombotic therapy in patients with atherosclerotic vascular disease is subject of several new therapeutic approaches. Simultaneous treatment with aspirin and a thienopyridin (clopidogrel) represents the standard of care for patients with acute coronary syndrome and following coronary stenting recommended by many guidelines. Without true
Antonio, Tello-Montoliu +2 more
+10 more sources
Expert Opinion on Investigational Drugs, 2006
Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyridine (a P2Y(12) receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes.
Udaya S, Tantry +2 more
openaire +4 more sources
Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyridine (a P2Y(12) receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes.
Udaya S, Tantry +2 more
openaire +4 more sources
International Journal of Cardiology, 2013
Recently, clopidogrel has beenproved to be reduced or complete lack of clinical benefit in nonsmokers in post-hoc analysis of several largescale randomized controlled trials (RCTs). These observations raise concerns about the costs and potential risks incurred by treating nonsmokers with clopidogrel [1].
Yicong, Ye +3 more
openaire +2 more sources
Recently, clopidogrel has beenproved to be reduced or complete lack of clinical benefit in nonsmokers in post-hoc analysis of several largescale randomized controlled trials (RCTs). These observations raise concerns about the costs and potential risks incurred by treating nonsmokers with clopidogrel [1].
Yicong, Ye +3 more
openaire +2 more sources
On the Metabolism of Prasugrel
Revista Española de Cardiología (English Edition), 2011Hemos leido con interes el editorial de los Dres. Freedman e Iafrati recientemente publicado en REVISTA ESPANOLA DE CARDIOLOGIA. En dicho editorial, se menciona que el prasugrel es un inhibidor del receptor P2Y12 que no se metaboliza en el higado y no parece verse afectado por la variabilidad de la isoenzima P450.
Carlos Felipe, Barrera-Ramírez +2 more
openaire +2 more sources
2015
A comprehensive profile of prasugrel HCl is reported herein with 158 references. A full description including nomenclature, formulae, elemental analysis, and appearance is included. Methods of preparation for prasugrel HCl, its intermediates, and derivatives are fully discussed.
Mahmoud M H, Al Omari +4 more
openaire +2 more sources
A comprehensive profile of prasugrel HCl is reported herein with 158 references. A full description including nomenclature, formulae, elemental analysis, and appearance is included. Methods of preparation for prasugrel HCl, its intermediates, and derivatives are fully discussed.
Mahmoud M H, Al Omari +4 more
openaire +2 more sources
Journal of Cardiovascular Medicine, 2014
Clopidogrel is a prodrug that undergoes extensive enteric clearance and requires two-stage hepatic activation by cytochrome P450 (CYP) enzymes. This metabolic pathway is susceptible to genetic polymorphisms, resulting in a variable platelet inhibitory effect.
Nuccia, Morici +5 more
openaire +2 more sources
Clopidogrel is a prodrug that undergoes extensive enteric clearance and requires two-stage hepatic activation by cytochrome P450 (CYP) enzymes. This metabolic pathway is susceptible to genetic polymorphisms, resulting in a variable platelet inhibitory effect.
Nuccia, Morici +5 more
openaire +2 more sources